{"id":798,"date":"2022-01-10T00:52:39","date_gmt":"2022-01-10T00:52:39","guid":{"rendered":"https:\/\/kellyintel.com\/?p=798"},"modified":"2024-01-26T15:52:14","modified_gmt":"2024-01-26T15:52:14","slug":"xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma","status":"publish","type":"post","link":"https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/","title":{"rendered":"XDNA: CRISPR Start-Ups Are Being Courted by Big Pharma – Mammoth & Bayer"},"content":{"rendered":"

CRISPR & Gene Editing companies are making waves in 2022, including start-ups, which is validating the technology’s promise on disrupting healthcare.<\/p>\n

News coming out of Berlin, Germany and Brisbane, California USA from Bayer AG and Mammoth Biosciences, Inc., is showing how “Big Pharma” is looking to partner with CRISPR start-up company. In a joint press release, the companies announced a strategic collaboration and option agreement for the use of Mammoth\u2019s CRISPR systems to develop in vivo<\/i> gene-editing therapies.<\/p>\n

The XDNA index has leading public companies who are developing in vivo gene editing technology.<\/p>\n

The statement<\/a> said:<\/p>\n

Mammoth Biosciences\u2019 groundbreaking gene-editing technology is a key enabling technology, as well as a stand-alone therapeutic modality. It will significantly enhance Bayer\u2019s efforts to develop transformative therapies for patients faster and strengthen the company\u2019s recently established new cell and gene therapy platform. Under the terms of the agreement the two companies will start their collaboration with a focus on liver-targeted diseases.<\/p><\/blockquote>\n

Barron’s covered the news by stating:<\/p>\n

The week began with Germany\u2019s Bayer<\/a><\/span> (BAYN.Germany) saying on Sunday that it will pay $40 million, and potentially $1 billion more, to work with Mammoth BioSciences, a privately held venture co-founded by Jennifer Doudna\u2014who won a Nobel Prize with Emmanuelle Charpentier for discovering the Crispr-Cas gene-editing technology. Monday, Pfizer<\/a><\/span> unveiled a $1.3 billion partnership with the gene-editing firm Beam Therapeutics<\/a><\/span> (BEAM).<\/p><\/blockquote>\n

To learn more about CRISPR & Gene Editing please visit the XDNA Index<\/a> page or watch the video below:<\/p>\n","protected":false},"excerpt":{"rendered":"

CRISPR & Gene Editing companies are making waves in 2022, including start-ups, which is validating the technology’s promise on disrupting healthcare. News coming out of Berlin, Germany and Brisbane, California USA from Bayer AG and Mammoth Biosciences, Inc., is showing how “Big Pharma” is looking to partner with CRISPR start-up company. In a joint press […]<\/p>\n","protected":false},"author":4,"featured_media":801,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"yoast_head":"\nXDNA: CRISPR Start-Ups Are Being Courted by Big Pharma - Mammoth & Bayer - Kelly Intelligence<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XDNA: CRISPR Start-Ups Are Being Courted by Big Pharma - Mammoth & Bayer - Kelly Intelligence\" \/>\n<meta property=\"og:description\" content=\"CRISPR & Gene Editing companies are making waves in 2022, including start-ups, which is validating the technology’s promise on disrupting healthcare. News coming out of Berlin, Germany and Brisbane, California USA from Bayer AG and Mammoth Biosciences, Inc., is showing how “Big Pharma” is looking to partner with CRISPR start-up company. In a joint press […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/\" \/>\n<meta property=\"og:site_name\" content=\"Kelly Intelligence\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-10T00:52:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-01-26T15:52:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kellyintel.com\/wp-content\/uploads\/2022\/01\/dna-g339b21368_1280.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Kevin Kelly\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@kellyintel\" \/>\n<meta name=\"twitter:site\" content=\"@kellyintel\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Kevin Kelly\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/\"},\"author\":{\"name\":\"Kevin Kelly\",\"@id\":\"https:\/\/kellyintel.com\/#\/schema\/person\/2b310b3d4dc418f2257f5bf54aff62e8\"},\"headline\":\"XDNA: CRISPR Start-Ups Are Being Courted by Big Pharma – Mammoth & Bayer\",\"datePublished\":\"2022-01-10T00:52:39+00:00\",\"dateModified\":\"2024-01-26T15:52:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/\"},\"wordCount\":257,\"publisher\":{\"@id\":\"https:\/\/kellyintel.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kellyintel.com\/wp-content\/uploads\/2022\/01\/dna-g339b21368_1280.jpg\",\"articleSection\":[\"CRISPR & Gene Editing\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/\",\"url\":\"https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/\",\"name\":\"XDNA: CRISPR Start-Ups Are Being Courted by Big Pharma - Mammoth & Bayer - Kelly Intelligence\",\"isPartOf\":{\"@id\":\"https:\/\/kellyintel.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kellyintel.com\/wp-content\/uploads\/2022\/01\/dna-g339b21368_1280.jpg\",\"datePublished\":\"2022-01-10T00:52:39+00:00\",\"dateModified\":\"2024-01-26T15:52:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/#primaryimage\",\"url\":\"https:\/\/kellyintel.com\/wp-content\/uploads\/2022\/01\/dna-g339b21368_1280.jpg\",\"contentUrl\":\"https:\/\/kellyintel.com\/wp-content\/uploads\/2022\/01\/dna-g339b21368_1280.jpg\",\"width\":1280,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kellyintel.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XDNA: CRISPR Start-Ups Are Being Courted by Big Pharma – Mammoth & Bayer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kellyintel.com\/#website\",\"url\":\"https:\/\/kellyintel.com\/\",\"name\":\"Kelly Intelligence\",\"description\":\"Traditional Investing. Innovative Thinking.\",\"publisher\":{\"@id\":\"https:\/\/kellyintel.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kellyintel.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/kellyintel.com\/#organization\",\"name\":\"Kelly Intelligence\",\"url\":\"https:\/\/kellyintel.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kellyintel.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/kellyintel.com\/wp-content\/uploads\/2022\/02\/Kelly-Logo-In-Line-Intelligence_Color.jpg\",\"contentUrl\":\"https:\/\/kellyintel.com\/wp-content\/uploads\/2022\/02\/Kelly-Logo-In-Line-Intelligence_Color.jpg\",\"width\":2085,\"height\":1042,\"caption\":\"Kelly Intelligence\"},\"image\":{\"@id\":\"https:\/\/kellyintel.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/twitter.com\/kellyintel\",\"https:\/\/www.linkedin.com\/company\/kellyintel\",\"https:\/\/www.youtube.com\/channel\/UCv_XTXFT8t4ZpPBqmMcvxXA\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/kellyintel.com\/#\/schema\/person\/2b310b3d4dc418f2257f5bf54aff62e8\",\"name\":\"Kevin Kelly\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kellyintel.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/de7f3ff3d0f3652696e5c45b781dfc45?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/de7f3ff3d0f3652696e5c45b781dfc45?s=96&d=mm&r=g\",\"caption\":\"Kevin Kelly\"},\"url\":\"https:\/\/kellyintel.com\/author\/kevin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XDNA: CRISPR Start-Ups Are Being Courted by Big Pharma - Mammoth & Bayer - Kelly Intelligence","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/","og_locale":"en_US","og_type":"article","og_title":"XDNA: CRISPR Start-Ups Are Being Courted by Big Pharma - Mammoth & Bayer - Kelly Intelligence","og_description":"CRISPR & Gene Editing companies are making waves in 2022, including start-ups, which is validating the technology’s promise on disrupting healthcare. News coming out of Berlin, Germany and Brisbane, California USA from Bayer AG and Mammoth Biosciences, Inc., is showing how “Big Pharma” is looking to partner with CRISPR start-up company. In a joint press […]","og_url":"https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/","og_site_name":"Kelly Intelligence","article_published_time":"2022-01-10T00:52:39+00:00","article_modified_time":"2024-01-26T15:52:14+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/kellyintel.com\/wp-content\/uploads\/2022\/01\/dna-g339b21368_1280.jpg","type":"image\/jpeg"}],"author":"Kevin Kelly","twitter_card":"summary_large_image","twitter_creator":"@kellyintel","twitter_site":"@kellyintel","twitter_misc":{"Written by":"Kevin Kelly","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/#article","isPartOf":{"@id":"https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/"},"author":{"name":"Kevin Kelly","@id":"https:\/\/kellyintel.com\/#\/schema\/person\/2b310b3d4dc418f2257f5bf54aff62e8"},"headline":"XDNA: CRISPR Start-Ups Are Being Courted by Big Pharma – Mammoth & Bayer","datePublished":"2022-01-10T00:52:39+00:00","dateModified":"2024-01-26T15:52:14+00:00","mainEntityOfPage":{"@id":"https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/"},"wordCount":257,"publisher":{"@id":"https:\/\/kellyintel.com\/#organization"},"image":{"@id":"https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/#primaryimage"},"thumbnailUrl":"https:\/\/kellyintel.com\/wp-content\/uploads\/2022\/01\/dna-g339b21368_1280.jpg","articleSection":["CRISPR & Gene Editing"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/","url":"https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/","name":"XDNA: CRISPR Start-Ups Are Being Courted by Big Pharma - Mammoth & Bayer - Kelly Intelligence","isPartOf":{"@id":"https:\/\/kellyintel.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/#primaryimage"},"image":{"@id":"https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/#primaryimage"},"thumbnailUrl":"https:\/\/kellyintel.com\/wp-content\/uploads\/2022\/01\/dna-g339b21368_1280.jpg","datePublished":"2022-01-10T00:52:39+00:00","dateModified":"2024-01-26T15:52:14+00:00","breadcrumb":{"@id":"https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/#primaryimage","url":"https:\/\/kellyintel.com\/wp-content\/uploads\/2022\/01\/dna-g339b21368_1280.jpg","contentUrl":"https:\/\/kellyintel.com\/wp-content\/uploads\/2022\/01\/dna-g339b21368_1280.jpg","width":1280,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/kellyintel.com\/xdna-gene-editing-crispr-start-ups-are-being-courted-by-big-pharma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kellyintel.com\/"},{"@type":"ListItem","position":2,"name":"XDNA: CRISPR Start-Ups Are Being Courted by Big Pharma – Mammoth & Bayer"}]},{"@type":"WebSite","@id":"https:\/\/kellyintel.com\/#website","url":"https:\/\/kellyintel.com\/","name":"Kelly Intelligence","description":"Traditional Investing. Innovative Thinking.","publisher":{"@id":"https:\/\/kellyintel.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kellyintel.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kellyintel.com\/#organization","name":"Kelly Intelligence","url":"https:\/\/kellyintel.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kellyintel.com\/#\/schema\/logo\/image\/","url":"https:\/\/kellyintel.com\/wp-content\/uploads\/2022\/02\/Kelly-Logo-In-Line-Intelligence_Color.jpg","contentUrl":"https:\/\/kellyintel.com\/wp-content\/uploads\/2022\/02\/Kelly-Logo-In-Line-Intelligence_Color.jpg","width":2085,"height":1042,"caption":"Kelly Intelligence"},"image":{"@id":"https:\/\/kellyintel.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/twitter.com\/kellyintel","https:\/\/www.linkedin.com\/company\/kellyintel","https:\/\/www.youtube.com\/channel\/UCv_XTXFT8t4ZpPBqmMcvxXA"]},{"@type":"Person","@id":"https:\/\/kellyintel.com\/#\/schema\/person\/2b310b3d4dc418f2257f5bf54aff62e8","name":"Kevin Kelly","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kellyintel.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/de7f3ff3d0f3652696e5c45b781dfc45?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/de7f3ff3d0f3652696e5c45b781dfc45?s=96&d=mm&r=g","caption":"Kevin Kelly"},"url":"https:\/\/kellyintel.com\/author\/kevin\/"}]}},"_links":{"self":[{"href":"https:\/\/kellyintel.com\/wp-json\/wp\/v2\/posts\/798"}],"collection":[{"href":"https:\/\/kellyintel.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kellyintel.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kellyintel.com\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/kellyintel.com\/wp-json\/wp\/v2\/comments?post=798"}],"version-history":[{"count":5,"href":"https:\/\/kellyintel.com\/wp-json\/wp\/v2\/posts\/798\/revisions"}],"predecessor-version":[{"id":899,"href":"https:\/\/kellyintel.com\/wp-json\/wp\/v2\/posts\/798\/revisions\/899"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kellyintel.com\/wp-json\/wp\/v2\/media\/801"}],"wp:attachment":[{"href":"https:\/\/kellyintel.com\/wp-json\/wp\/v2\/media?parent=798"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kellyintel.com\/wp-json\/wp\/v2\/categories?post=798"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kellyintel.com\/wp-json\/wp\/v2\/tags?post=798"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}